2021-2023年中国东南部福建省基于人群的癌症生存分析

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2025-06-16 DOI:10.1016/j.canep.2025.102866

Zhisheng Xiang , Jingyu Ma , Yeying Wen , Yongtian Lin , Yongying Huang , Linrong Wu , Yan Zhou , Chuanben Chen

{"title":"2021-2023年中国东南部福建省基于人群的癌症生存分析","authors":"Zhisheng Xiang , Jingyu Ma , Yeying Wen , Yongtian Lin , Yongying Huang , Linrong Wu , Yan Zhou , Chuanben Chen","doi":"10.1016/j.canep.2025.102866","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Population-based survival data is commonly used to evaluate the effectiveness of cancer prevention and treatment. This study aims to assess the 5-year relative survival of patients with cancer in Fujian Province, southeastern China, between 2021 and 2023.</div></div><div><h3>Methods</h3><div>The new cases of cancer in 25 cancer registries in Fujian Province from 2016 to 2021 were included in this study, and patients’ survival status was followed up until March 1, 2024. The hybrid method was used to calculate cancer relative survival by gender, region and age (2021–2023), and results were standardized according to International Cancer Survival Standards Weights.</div></div><div><h3>Results</h3><div>There were 184,216 patients were included in the study after quality control, including 101,338 males and 82,878 females. The 5-year relative survival for all cancers combined was 51.7 %, and the age-standardized 5-year relative survival was 43.8 % in 2021–2023. The age-standardized 5-year relative survival was higher in females than males (52.7 % and 36.3 %). The survival in urban was higher than that in rural areas (49.3 % and 37.9 %). The three types of cancer with the highest survival in males were thyroid (94.5 %), testicular (77.7 %), bladder (69.1 %). In females, thyroid cancer (94.9 %), breast cancer (77.6 %) and bladder cancer (72.1 %) were the three cancers with the highest survival. Most cancer survival was higher in females than in males. The relative survival decreased with age, the highest survival was 79.5 % in the age group under 45 years old and the lowest survival was 21.8 % in the age 75 and above.</div></div><div><h3>Conclusions</h3><div>The cancer survival rates in Fujian Province have reached the goal of Healthy China 2030, but there is still a gap with high survival areas. To narrow this gap, more targeted interventions are needed to further improve cancer survival.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"97 ","pages":"Article 102866"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A population-based analysis of cancer survival in Fujian Province, southeast China during 2021–2023\",\"authors\":\"Zhisheng Xiang , Jingyu Ma , Yeying Wen , Yongtian Lin , Yongying Huang , Linrong Wu , Yan Zhou , Chuanben Chen\",\"doi\":\"10.1016/j.canep.2025.102866\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Population-based survival data is commonly used to evaluate the effectiveness of cancer prevention and treatment. This study aims to assess the 5-year relative survival of patients with cancer in Fujian Province, southeastern China, between 2021 and 2023.</div></div><div><h3>Methods</h3><div>The new cases of cancer in 25 cancer registries in Fujian Province from 2016 to 2021 were included in this study, and patients’ survival status was followed up until March 1, 2024. The hybrid method was used to calculate cancer relative survival by gender, region and age (2021–2023), and results were standardized according to International Cancer Survival Standards Weights.</div></div><div><h3>Results</h3><div>There were 184,216 patients were included in the study after quality control, including 101,338 males and 82,878 females. The 5-year relative survival for all cancers combined was 51.7 %, and the age-standardized 5-year relative survival was 43.8 % in 2021–2023. The age-standardized 5-year relative survival was higher in females than males (52.7 % and 36.3 %). The survival in urban was higher than that in rural areas (49.3 % and 37.9 %). The three types of cancer with the highest survival in males were thyroid (94.5 %), testicular (77.7 %), bladder (69.1 %). In females, thyroid cancer (94.9 %), breast cancer (77.6 %) and bladder cancer (72.1 %) were the three cancers with the highest survival. Most cancer survival was higher in females than in males. The relative survival decreased with age, the highest survival was 79.5 % in the age group under 45 years old and the lowest survival was 21.8 % in the age 75 and above.</div></div><div><h3>Conclusions</h3><div>The cancer survival rates in Fujian Province have reached the goal of Healthy China 2030, but there is still a gap with high survival areas. To narrow this gap, more targeted interventions are needed to further improve cancer survival.</div></div>\",\"PeriodicalId\":56322,\"journal\":{\"name\":\"Cancer Epidemiology\",\"volume\":\"97 \",\"pages\":\"Article 102866\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877782125001262\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782125001262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

基于人群的生存数据通常用于评估癌症预防和治疗的有效性。本研究旨在评估2021年至2023年中国东南部福建省癌症患者的5年相对生存期。方法选取2016 - 2021年福建省25个癌症登记处的新发癌症病例，随访至2024年3月1日。采用混合方法按性别、地区和年龄计算癌症相对生存率（2021-2023），并根据国际癌症生存标准权重对结果进行标准化。结果经质量控制共纳入184216例患者，其中男性101338例，女性82878例。2021-2023年，所有癌症的5年相对生存率为51.7 %，年龄标准化的5年相对生存率为43.8% %。年龄标准化5年相对生存率女性高于男性（52.7% %和36.3% %）。城市的生存率高于农村（49.3% %和37.9% %）。男性生存率最高的三种癌症分别是甲状腺癌（94.5 %）、睾丸癌（77.7 %）和膀胱癌（69.1 %）。在女性中，甲状腺癌（94.9 %）、乳腺癌（77.6% %）和膀胱癌（72.1 %）是生存率最高的三种癌症。大多数癌症患者中，女性的存活率高于男性。相对生存率随年龄增长而降低，45岁以下生存率最高，为79.5 %，75岁及以上生存率最低，为21.8% %。结论福建省肿瘤生存率已达到“健康中国2030”目标，但与高生存区仍有差距。为了缩小这一差距，需要更有针对性的干预措施来进一步提高癌症存活率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A population-based analysis of cancer survival in Fujian Province, southeast China during 2021–2023

Background

Population-based survival data is commonly used to evaluate the effectiveness of cancer prevention and treatment. This study aims to assess the 5-year relative survival of patients with cancer in Fujian Province, southeastern China, between 2021 and 2023.

Methods

The new cases of cancer in 25 cancer registries in Fujian Province from 2016 to 2021 were included in this study, and patients’ survival status was followed up until March 1, 2024. The hybrid method was used to calculate cancer relative survival by gender, region and age (2021–2023), and results were standardized according to International Cancer Survival Standards Weights.

Results

There were 184,216 patients were included in the study after quality control, including 101,338 males and 82,878 females. The 5-year relative survival for all cancers combined was 51.7 %, and the age-standardized 5-year relative survival was 43.8 % in 2021–2023. The age-standardized 5-year relative survival was higher in females than males (52.7 % and 36.3 %). The survival in urban was higher than that in rural areas (49.3 % and 37.9 %). The three types of cancer with the highest survival in males were thyroid (94.5 %), testicular (77.7 %), bladder (69.1 %). In females, thyroid cancer (94.9 %), breast cancer (77.6 %) and bladder cancer (72.1 %) were the three cancers with the highest survival. Most cancer survival was higher in females than in males. The relative survival decreased with age, the highest survival was 79.5 % in the age group under 45 years old and the lowest survival was 21.8 % in the age 75 and above.

Conclusions

The cancer survival rates in Fujian Province have reached the goal of Healthy China 2030, but there is still a gap with high survival areas. To narrow this gap, more targeted interventions are needed to further improve cancer survival.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.